Dr. Isabel Varela-Nieto graduated and earned her doctorate in Chemistry, Biochemistry Section, at the University Complutense of Madrid (Spain). She has been a visiting guest scientist at the Medical Schools of Uppsala (FEBS Fellow, Sweden) and San Diego (MEC Sabbatical, USA). She is Professor of Research at the CSIC and group leader at the CIBER of rare diseases (CIBERER, ISCIII) in Madrid. From the early 1990s she has been studying hearing neurobiology and IGF-1 actions. She was the first Chair of the SEBBM Science for Society working group with which she actively collaborates, and member of the FEBS Network working group. She is currently the president of the SEBBM, a member of the FEBS Science and Society Committee and of the ISC Finances Committee.

iam graduated from faculty of science, chemistry and biochemistry dep. i have a biomedical analysis diploma. my master degree focused in treatment diabetes with the combination therapy using natural products and a pharmaceutical. i hope to find a PHD position in biochemistry. mainly my interest in biochemistry. title of thesis( treatment of HFD induced diabetes with combination of metformin and natural products)

The Hungarian Biochemical Society (HBS) is one of the eight founding members of FEBS. The aim of HBS is to support the work of Hungarian biochemists, molecular biologists and biotechnologists to increase the quality of research and education in molecular life sciences in the frame of universities and research centers of the Hungarian Academy of Sciences. From the beginnings, HBS hosts regular meetings, methodological presentations and workshops, including three FEBS3+ conferences jointly organized with the Slovenian, Croatian and Serbian Societies. These provide the first opportunities for young researchers to present and critically discuss their results and to establish new professional relationships. HBS publishes the quarterly journal “Biokémia” including news and events of the Society, international scientific social issues, historical reviews and scientific publications. For over five decades, HBS significantly contributed to the work of FEBS committees and the editorial offices of its Journals and organized the 9th and 20th FEBS Meetings (1974, 1990) and the 30th FEBS Congress-9th IUBMB Conference (2015) in Budapest.

Genomic Instability DNA metabolism DNA Damage Molecular Oncology Stem cells DNA replication Gene expression Xenopus system

Dr. Petar Ozretić is a Senior Research Associate and Head of the Laboratory for Hereditary Cancer at the Ruđer Bošković Institute (RBI) in Zagreb, Croatia. After receiving a Diploma degree in Molecular Biology at the Faculty of Science, University of Zagreb in 2005, he was employed as a Professional Associate at the RBI in 2006. Under the mentorship of Prof. Sonja Levanat and Prof. Alberto Inga, he obtained a PhD degree in Biomedicine and Health in 2013. He was a Senior Assistant at the RBI until 2017 when he was promoted to a Research Associate. He is an Adjunct Assistant Professor at the JJ Strossmayer University of Osijek from 2018. He mentored one PhD and seven Diploma theses. He was participating in 25 projects as an associate or PI. His research interests include regulation of the Hedgehog signaling pathway by ncRNAs, interaction between SHH protein and sex hormone receptors, and the role of m1A RNA modification in head and neck tumors. He is a member of the Editorial Council of Libri Oncologioci Croatian Journal of Oncology, a Technical Editor of Periodicum biologoum journal, reviewer for numerous journals (reviewed more than 700 manuscripts). He has published 58 scientific articles, which have been cited ~1500 times (Google Scholar's H-index 20). He is a member of 10 professional associations, and from 2009 he is a Secretary of the Croatian Association for Cancer Research (HDIR), national society affiliated to the European Association for Cancer Research (EACR).

Molecular Oncology is an Open Access international journal that highlights new discoveries, approaches, as well as technical developments, in basic, clinical and discovery-driven translational cancer research.